The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...

Brian Lisankie to lead strategic growth and operations in the region, bringing decades of leadership experience to the role.

Alvotech posted the largest decline among large stocks during the session, declining 5.3%, followed by Orkla ASA shares, which dropped 4.0%. Shares of Camurus AB dropped 3.8%.

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the ...

Promising Systemic Sclerosis Pipeline Therapies such as Divozilimab, Avenciguat (BI 685509), Nintedanib, GSK2330811, ...